What Ray Therapeutics does

Ray Therapeutics is a clinical-stage biotechnology company founded in 2021 that develops optogenetic gene therapies intended to restore vision in patients with advanced, blinding retinal diseases. The company's core technology is a proprietary platform that uses bioengineered, highly light-sensitive channelrhodopsin proteins — notably ChRown — delivered via AAV-based gene therapy to reprogram surviving retinal neurons (ganglion cells or ON-bipolar cells, depending on the program) into functional photosensors that transmit visual signals to the brain. Because the approach is mutation-agnostic, it can in principle address retinitis pigmentosa, choroideremia, Stargardt disease, and geographic atrophy secondary to AMD through a single intravitreal injection intended as a one-time, lifelong treatment that does not require light-enhancing eyewear.

The pipeline is currently materialized in two named clinical-stage candidates: RTx-015 (lead), which targets retinal ganglion cells and is being evaluated in the ENVISION Phase 1 trial (NCT06460844) for retinitis pigmentosa and choroideremia, having received both FDA Regenerative Medicine Advanced Therapy (RMAT) designation and European Medicines Agency Priority Medicines (PRIME) designation in April 2026; and RTx-021, which targets retinal ON-bipolar cells and is being advanced for Stargardt disease and geographic atrophy (secondary to AMD).

Ray Therapeutics is pre-revenue and funds its operations through a syndicate of life-sciences venture and crossover investors and California Institute for Regenerative Medicine (CIRM) grants. Cumulative capital raised to date includes a $6M seed (2022, 4BIO Capital), a $100M Series A (2023, Novo Holdings A/S lead), a $125M Series B (2026, Janus Henderson Investors lead), and CIRM grants of $4M (2022), $4M (2023) and $8M (2025). Manufacturing is enabled through a CDMO partnership with Forge Biologics for AAV process development, scale-up, cGMP manufacturing, and plasmid DNA production. The expected go-to-market is a specialty ophthalmology commercial model leveraging one-time gene-therapy pricing typical of rare-disease retinal therapeutics, with U.S. as primary market and Europe signaled via the PRIME designation.

Name

Ray Therapeutics

Legal name

Ray Therapeutics, Inc.

Website

https://raytherapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Ray Therapeutics is a clinical-stage biotechnology company developing bioengineered optogenetic gene therapies delivered via a single intravitreal injection to restore vision in patients with blinding retinal diseases such as retinitis pigmentosa and choroideremia.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Optogenetic gene therapy
• Retinal disease therapy
• AAV gene therapy
• Ophthalmic biotechnology
• Inherited retinal diseases

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue clinical-stage gene therapy: Ray Therapeutics is a clinical-stage biopharmaceutical company with no commercial product revenue; future revenue model is expected to be one-time gene therapy treatments administered via single intravitreal injection (a unit-pricing/one-time-payment biotech model) delivered to patients with advanced retinal degeneration.
2. Non-dilutive grant funding (CIRM): Receives milestone-based grant funding from the California Institute for Regenerative Medicine (CIRM) — including a $4M grant (CLIN2-17086) and an $8M award — supporting clinical development of optogenetic programs.
3. Private equity financing: Capital raised via priced equity rounds: $6M seed (2022), $100M Series A (2023), $125M Series B (2026) from a syndicate of life-sciences venture and crossover investors.

Go-to-market motion3 records

Core offering

Ray Therapeutics is a clinical-stage biopharmaceutical company developing bioengineered optogenetic gene therapies that use light-sensitive channelrhodopsin proteins delivered via AAV-based gene therapy to reprogram surviving retinal neurons, restoring visual signal transmission to the brain. Its lead candidate RTx-015 (intravitreal, retinal ganglion cell targeting) is in a Phase 1 ENVISION trial for retinitis pigmentosa and choroideremia, and a second candidate RTx-021 (retinal ON-bipolar cell targeting) is advancing for Stargardt disease and Geographic Atrophy secondary to AMD.

Product overview

Ray Therapeutics operates a single integrated optogenetics product platform rather than a multi-product software suite. The platform bioengineers and delivers light-sensitive channelrhodopsin proteins to surviving retinal neurons via AAV-based gene therapy, and is currently materialized in two named clinical-stage product candidates: RTx-015 (lead, targeting retinal ganglion cells for retinitis pigmentosa and choroideremia, in Phase 1 ENVISION trial and holding FDA RMAT and EMA PRIME designations) and RTx-021 (targeting retinal ON-bipolar cells for Stargardt Disease and Geographic Atrophy secondary to AMD, in late-stage preclinical/early clinical development). The pipeline is mutation-agnostic and intended as one-time intravitreal treatments providing lifelong vision restoration.

Differentiator

Problem solved

Functional benefit

Brands

• RTx-015: Lead optogenetic gene therapy candidate of Ray Therapeutics, administered as a single intravitreal injection and being evaluated in a Phase 1 clinical trial (ENVISION) for retinitis pigmentosa and choroideremia; granted FDA RMAT designation (April 2026) and EMA PRIME designation (April 2026).
• RTx-021
• Ray-001

Products and services

• RTx-015 First-in-class, genotype-independent optogenetic gene therapy administered as a single intravitreal injection that bioengineers and delivers a highly light-sensitive channelrhodopsin protein (ChRown) to retinal ganglion cells, reprogramming them to act as photosensors that send visual signals to the brain. Lead indication is retinitis pigmentosa, with the Phase 1 ENVISION trial also enrolling choroideremia patients; received FDA RMAT and EMA PRIME designations in 2026.
• RTx-021 Optogenetic gene therapy designed to restore vision in macular diseases such as Stargardt disease and Geographic Atrophy secondary to age-related macular degeneration (GA AMD) by targeting retinal ON-bipolar cells with a bioengineered light-sensitive protein. Late-stage preclinical/clinical-stage development supported by CIRM grants.
• Ray Therapeutics Optogenetics Platform Proprietary bioengineered optogenetics platform that uses light-sensitive naturally evolved channelrhodopsin proteins to reprogram surviving retinal neurons to sense light and transmit visual signals to the brain. The platform underpins the company's mutation-agnostic, single-dose gene therapies and supports the RTx-015 and RTx-021 programs; designed to provide lifelong benefits without requiring light-enhancing eyewear.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• REGENXBIO: Clinical and commercial-stage AAV gene therapy company with multiple ophthalmology and CNS programs, including ABBV-RGX-314 for wet AMD (in-licensed to AbbVie). A larger incumbent with broad AAV platform applicability rather than a focused optogenetics niche.
• Spark Therapeutics (Roche): Pioneering ocular gene therapy company and developer of Luxturna (voretigene neparvovec), the only FDA-approved retinal gene therapy. Now part of Roche, Spark represents the only fully validated commercial precedent for AAV retinal gene therapy.

Direct peers

• MeiraGTx: Clinical-stage gene therapy company with a portfolio that includes AAV-based therapies for inherited retinal diseases (e.g., RP, achromatopsia) and other ocular indications. Closely comparable technology platform and clinical stage.
• Nanoscope Therapeutics: Clinical-stage biotech developing MCO-010, an ambient-light-sensitive optogenetic gene therapy for retinitis pigmentosa and Stargardt disease. Direct competitor in optogenetic retinal gene therapy, but materially further advanced (Phase 2b/3) than Ray's RTx-015.
• 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with multiple ophthalmology programs (e.g., 4D-150 for wet AMD and diabetic macular edema) and a directed-evolution AAV platform. Ray's CMSO and CDO are former 4DMT executives, highlighting deep operational overlap.
• Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec), an intravitreal AAV-based therapy for wet AMD and diabetic eye disease. Directly comparable as an intravitreal AAV gene therapy targeting retinal disease.
• SparingVision: Paris-based clinical-stage gene therapy company developing SPVN-06, a mutation-agnostic optogenetic therapy for rod-cone dystrophies including RP. Closest European peer in the optogenetic retinal space.
• Beacon Therapeutics (formerly AGTC): Clinical-stage gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa (XLRP) and other inherited retinal diseases. Closely comparable indication portfolio and AAV-delivery approach.

Emerging players

• EyePoint Pharmaceuticals: Clinical-stage ocular therapeutics company developing sustained-release intravitreal treatments (e.g., EYP-1901 for wet AMD and diabetic macular edema) using its Durasert bioerodible technology. Comparable in intravitreal delivery and ophthalmic focus, though not a gene therapy.
• Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies including EDIT-101 for Leber congenital amaurosis 10 (LCA10). Comparable in retinal disease focus but uses gene editing rather than optogenetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ray-therapeutics-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ray Therapeutics